Sysmex Scientific Seminar
Outline
46th(2024) Sysmex Scientific Seminar
| Date/Time | June 8th, 2024 10:00am-4:05pm (JST) |
|---|---|
| Format | Webinar |
Ken-ichi Hirata
Professor Emeritus, Kobe University / President, Kakogawa Central City Hospital
Sysmex Scientific Seminar Planning Committee
Interview with Ken-ichi Hirata
(Planner, 46th Sysmex Scientific Seminar)
Sysmex Scientific Seminar Guide
The topic of "Future Prospects for Cardiovascular Disease Research"
is extremely important for our healthy lifespan. Heart disease and vascular disorders have become one of the most serious health and medical challenges in modern society. Advances in medical technology associated with cardiovascular disease research hold promise for the future of the field of cardiovascular healthcare.
We will present the latest information from four specialized physicians, providing a real sense of the progress made. The content of the event will be advantageous not only cardiovascular physicians but also for medical technoligists. We encourage you to take this opportunity to participate.
Cardiovascular disease is the leading cause of death worldwide
1. Leading causes of death globally
<The top 10 causes of death>
In 2019, the top 10 causes of death accounted for 55% of the 55.4 million deaths worldwide.
The top global causes of death, in order of total number of lives lost, are associated with three broad topics: cardiovascular (ischaemic heart disease, stroke), respiratory (chronic obstructive pulmonary disease, lower respiratory infections) and neonatal conditions – which include birth asphyxia and birth trauma, neonatal sepsis and infections, and preterm birth complications.
Source：「The top 10 causes of death」（WHO）
https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
2. Cardiovascular disease risk factors and mortality around the world
The world’s biggest killer is ischaemic heart disease, responsible for 16% of the world’s total deaths. Since 2000, the largest increase in deaths has been for this disease, rising by more than 2 million to 8.9 million deaths in 2019. Stroke and chronic obstructive pulmonary disease are the 2nd and 3rd leading causes of death, responsible for approximately 11% and 6% of total deaths respectively.
Program / Abstracts
| Time*JST | Agenda |
|---|---|
| 10:00-10:05 |
Opening Address
Yutaka Yatomi, M.D., Ph.D. Chairperson of Sysmex Scientific Seminar planning committee |
| 10:05-10:55 |
Abstracts / Curriculum Vitae
AbstractThe Future of Cardiovascular MedicineAs Japan becomes a super-aged society, the disease structure is changing, and the number of patients with cardiovascular diseases such as heart failure and atrial fibrillation that develop with age is rapidly increasing. In particular, heart failure, the terminal manifestation of all cardiovascular diseases, has become a major problem, with the number of patients and deaths increasing. Although progress has been made in the treatment of heart failure with both pharmacological and non-pharmacological therapies, most therapies are limited to symptomatic treatments such as cardioprotection and cardiac replacement, and molecular targeted therapies based on the pathogenesis of the disease, such as those for cancer, have not been developed. Cardiovascular disease is an "ultra-complex system" in which genetic and environmental factors are intricately intertwined, making it difficult to elucidate the pathogenesis. Heart failure, in particular, is an even more challenging problem because not only do numerous genetic and environmental factors play a role in its pathogenesis, but it is also a dynamic problem that must ultimately be solved through the contraction and relaxation of the heart. However, recent advances in data science have made it possible to analyze the pathogenesis of cardiovascular diseases, including heart failure, with more information than any other disease. Curriculum Vitae
|
| 10:55-11:10 |
QA
|
| 11:10-12:00 |
Abstracts / Curriculum Vitae
AbstractHow can we prevent cardiovascular aging?The incidence of lifestyle-related diseases increases with age and, as a result, is the underlying pathology for the development of ischemic heart disease and stroke. These diseases, which shorten healthy life expectancy, can be viewed as part of the traits of aging, as they are commonly observed in many elderly people. In other words, the ultimate target for treatment of these diseases may be the mechanisms that regulate life span itself. In this current situation, research on the mechanisms of aging and lifespan has made tremendous progress in the last 20 years. There are many theories on the mechanisms of aging, one of which is the "cellular aging hypothesis". This hypothesis proposes that aging and metabolic stresses such as overeating cause the accumulation of senescent cells in various tissues, which in turn cause tissue damage and impair tissue regeneration through the secretion of inflammatory molecules, resulting in organ and individual cells aging. In fact, we have shown that the accumulation of senescent cells in blood vessels, heart, and visceral adipose tissue is involved in the onset and progression of atherosclerosis, heart failure, and diabetes, respectively. Furthermore, it has recently been shown that senescent cell removal (senolysis) ameliorates pathological aging traits. In this article, we would like to discuss the possibility of anti-aging therapies targeting senescent cells (seno-antigen, seno-anergy-related molecules). Curriculum VitaeEducation
Postdoctoral Training:Internships and Residencies:
Research Fellowships:
|
| 12:00-12:15 |
QA
|
| 12:15-13:35 |
Break
|
| 13:35-14:25 |
Abstracts / Curriculum Vitae
AbstractPrecision medicine for primary dyslipidemias and atherosclerotic cardiovascular diseasesArteriosclerotic diseases are a major cause of death not only in Japan but also worldwide, and overcoming them is extremely important. Dyslipidemia, the greatest risk factor for atherosclerotic diseases, is an inherited trait, and genetic research has been conducted for its prevention and treatment. Dyslipidemia is not only a risk factor for atherosclerotic diseases, but also a cause of them. In this lecture, I would like to introduce genomic medicine as medical treatment and research, focusing on familial hypercholesterolemia (FH), the most appropriate and frequent monogenic disease related to this topic. I will also discuss the current efforts towards ultra-precision personalized medicine for similar primary lipid disorders and atherosclerotic disease. Additionally, I will present the current status and future developments of ultra-precise personalized medicine based on genetic polygenic risk scores. Curriculum Vitae
|
| 14:25-14:40 |
QA
|
| 14:40-14:55 |
Break
|
| 14:55-15:45 |
Abstracts / Curriculum Vitae
AbstractAddressing Unmet Needs in the Cardiovascular Area by Industry-Academia Collaboration: Establishment of a Novel Method to Assess HDL functionalityIn Japan, where the population is aging at a rate unparalleled in the world, the extension of healthy life expectancy is an urgent issue. As a countermeasure against cardiovascular disease, which is a major cause of conditions requiring long-term care, we have been working with Sysmex Corporation to develop a method to evaluate high-density lipoprotein (HDL) function, although hypo-HDL cholesterolemia is one of the residual risks of cardiovascular disease after LDL cholesterol lowering therapy. Recently, it has been suggested that HDL is important not only in quantity but also in quality. However, there is no established method to assess HDL function, which has been a barrier to the development of HDL-targeted prevention and treatment strategies. Therefore, we have proposed the cholesterol uptake capacity (CUC) as a new clinically applicable HDL functional index, and have demonstrated its clinical usefulness. Recently, we have completed a fully automated measurement system with high reproducibility, which enables high-throughput evaluation of CUC and provides an environment in which real-world evidence can be established. At the same time, the company is also working on the development of new biomarker discovery and testing methods, utilizing the know-how cultivated through past industry-academia co-creation. In addition, accurate understanding of the current situation is essential in disease control. We are conducting the KUNIUMI registry on Awaji Island, Hyogo Prefecture, with the aim of understanding the issues involved in the treatment of heart failure in a super-aging society. Curriculum Vitae
Education:
|
| 15:45-16:00 |
QA
|
| 16:00-16:05 |
Closing Address
Ken-ichi Hirata, M.D., Ph.D. Planner of the 46th Sysmex Scientific Seminar |
About
Sysmex Scientific Seminar is an annual seminar held by Sysmex Corporation, with the aim of contributing to medical care.
In recent years, basic, laboratory, and clinical medicine have come closer together, and the speed of change has been accelerating.
In line with this change, the seminar has been focusing on medical research that is closely related to our business domain of clinical testing.
A wide range of topics are covered in the seminar, including bone marrow medical science, autoimmune diseases, genetic testing, regenerative medicine, and more.
We will continue our efforts to provide up-to-date information that will enable you to experience the progress of today's medical science.
Sysmex Scientific Seminar is a purely academic seminar devoid of corporate PR.
Over the past 45 years, more than 45,000 people have participated in the event, which has also been live-streamed overseas,
People from 18 countries have watched the event, and a total of approximately 3,500 people have participated, both domestically and internationally(as of 2022).
Archives
On the Sysmex Scientific Seminar Member's page, you can watch videos of past Sysmex Scientific Seminars and download PDF versions of the texts.
If you wish to view the videos, please click "seminar videos and PDF texts" to proceed to the registration form.
45th(2023) Sysmex Scientific Seminar
Wide Connection Between Blood and Systemic Organs
Highlight of the 45th Sysmex Scientific Seminar
-
- Plenary Lecture: Clonal Hematopoiesis and Relevant Diseases
- Speaker: Seishi Ogawa, M.D., Ph.D.
(Professor, Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University)
- Lecture 1: Genetic Landscape of Clonal Hematopoiesis in the Japanese Population
- Speaker: Ryunosuke Saiki, M.D., Ph.D.
(Assistant Professor, Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University)
- Lecture 2: Clonal Hematopoiesis and Cardiovascular Disease
-
Speaker: Yasuchika Takeishi, M.D., Ph.D.
(President, Fukushima Medical University Hospital Professor and Chairman, Department of Cardiovascular Medicine, Fukushima Medical University)
- Lecture 3: Acquired Aplastic Anemia and Clonal Hematopoiesis
-
Speaker: Kohei Hosokawa, M.D., Ph.D.
(Associate Professor, Department of Hematology, Kanazawa University Hospital)
- Lecture 4: Clonal Hematopoiesis as an Origin for Malignant Lymphomas
-
Speaker: Mamiko Sakata-Yanagimoto, M.D., Ph.D.
(Professor, Department of Hematology, Faculty of Medicine, University of Tsukuba, Professor, Transborder Medical Research Center, University of Tsukuba)